Currently, immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are regarded as standard methods for the determination of HER2 status in breast cancer, and some of them have been approved by the U.S. Food and Drug Administration (FDA) for HER2 testing in breast cancer since 1998 [13]. This evidence concerns the gene ERBB2 and breast cancer.